Sparks commentary

Healthcare

Sparks

Isofol Medical (ST: ISOFOL) completes pre-IND meeting for arfolitixorin
Published by Arron Aatkar, PhD

Isofol Medical has announced the completion of a pre-IND meeting with the FDA for arfolitixorin. According to management, the meeting was a success, with the FDA providing positive feedback on the company’s clinical development plan for the candidate. This is an important milestone for Isofol, as it provides a foundation for further development efforts and potential eventual commercialisation in the US.

Isofol is currently evaluating arfolitixorin in a Phase Ib/II trial as a potential treatment for patients with metastatic colorectal cancer.

Latest

TMT | Comment

Cordel – Positive progress with PTC

Healthcare | Comment

Cantargia (OMX: CANTA): CAN10 programme acquired by Otsuka

Energy & Resources | Comment

bp (BP:LSE) – Updated Q225 guidance

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free